Advertisement

Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis

Authors

  • Julie M. Hall,

    Corresponding author
    1. College of Pharmacy and Health Sciences, Campbell University, Buies Creek, North Carolina
    • College of Pharmacy and Health Sciences, Campbell University, P.O. Box 1090, Buies Creek, NC 27506.
    Search for more papers by this author
  • Kenneth S. Korach

    1. Laboratory of Reproductive and Developmental Toxicology, Receptor Biology Section, The National Institutes of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina
    Search for more papers by this author

Abstract

The majority of ovarian cancers over-express the estrogen receptor (ERα) and grow in response to estrogens. We previously demonstrated that ER induction of the chemokine CXCL12 (stromal cell-derived factor-1) is required for estradiol (E2)-stimulated proliferation of human ovarian carcinoma cells. In the current study, we report that known “endocrine disrupting chemicals” (EDCs) display mitogenic activities in ovarian cancer cells via their ability to activate the ER and upregulate CXCL12 expression. Notably, the EDCs genistein, bisphenol A and HPTE stimulated both cell proliferation and induction of CXCL12 mRNA and protein in a manner comparable to estradiol. The effects were completely attenuated by the ER antagonist ICI 182,780, revealing that observed activities of these agents were receptor-mediated. In cell proliferation assays, the mitogenic effects of estradiol and EDCs were obviated by siRNAs targeting CXCL12 and restored upon addition of exogenous CXCL12. Furthermore, an inhibitor to the CXCL12 receptor CXCR4 completely attenuated growth-stimulatory effects of E2 and EDCs. These studies highlight a potential role of EDCs possessing estrogenic activities in the etiology of ovarian cancer. Moreover, they suggest that the ER-CXCL12-CXCR4 signaling axis may represent a promising target for development of therapeutics for ER+ ovarian cancers. © 2012 Wiley Periodicals, Inc.

Ancillary